New Zealand markets closed

Corvus Pharmaceuticals, Inc. (CRVS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.4000-0.0100 (-0.71%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 70.13M
Enterprise value 44.35M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.81
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.91

Trading information

Stock price history

Beta (5Y monthly) 1.02
52-week change 333.02%
S&P500 52-week change 321.23%
52-week high 34.1900
52-week low 30.9780
50-day moving average 31.9587
200-day moving average 31.8651

Share statistics

Avg vol (3-month) 3199.09k
Avg vol (10-day) 3143k
Shares outstanding 549.04M
Implied shares outstanding 649.04M
Float 834.4M
% held by insiders 13.89%
% held by institutions 139.96%
Shares short (28 Mar 2024) 41.4M
Short ratio (28 Mar 2024) 45.82
Short % of float (28 Mar 2024) 43.79%
Short % of shares outstanding (28 Mar 2024) 42.85%
Shares short (prior month 29 Feb 2024) 41.27M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-25.63%
Return on equity (ttm)-57.02%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -23.18M
Net income avi to common (ttm)-27.03M
Diluted EPS (ttm)-0.5600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)27.15M
Total cash per share (mrq)0.55
Total debt (mrq)1.37M
Total debt/equity (mrq)3.55%
Current ratio (mrq)4.07
Book value per share (mrq)0.79

Cash flow statement

Operating cash flow (ttm)-23.93M
Levered free cash flow (ttm)-15.79M